Trial Profile
Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 12 May 2017 New trial record